PubRank

Y G Assaraf

Author PubWeight™ 30.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999 1.72
2 Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 2011 1.29
3 Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem 1999 1.14
4 A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998 1.08
5 Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 1995 1.00
6 Polyamine levels and the activity of their biosynthetic enzymes in human erythrocytes infected with the malarial parasite, Plasmodium falciparum. Biochem J 1984 0.97
7 Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 2004 0.97
8 The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 2012 0.96
9 Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death Dis 2012 0.95
10 Cytostatic effect of DL-alpha-difluoromethylornithine against Plasmodium falciparum and its reversal by diamines and spermidine. Parasitol Res 1987 0.94
11 The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 1996 0.94
12 Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 1996 0.92
13 Effect of polyamine depletion on macromolecular synthesis of the malarial parasite, Plasmodium falciparum, cultured in human erythrocytes. Biochem J 1987 0.92
14 Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur J Biochem 1997 0.92
15 The pattern of dihydrofolate reductase expression through the cell cycle in rodent and human cultured cells. J Biol Chem 1989 0.92
16 Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer 2011 0.91
17 A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 1998 0.90
18 Plasmodium falciparum: synchronization of cultures with DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis. Exp Parasitol 1986 0.89
19 The effect of purified aminoaldehydes produced by polyamine oxidation on the development in vitro of Plasmodium falciparum in normal and glucose-6-phosphate-dehydrogenase-deficient erythrocytes. Biochem J 1986 0.88
20 Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem 2000 0.83
21 Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999 0.83
22 Alteration of mitochondrial gene expression and disruption of respiratory function by the lipophilic antifolate pyrimethamine in mammalian cells. J Biol Chem 1995 0.83
23 A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J Biol Chem 1998 0.83
24 Flow cytometric characterization of antifolate resistance in cultured mammalian cells using fluoresceinated methotrexate and daunorubicin. Cancer Res 1990 0.82
25 Transport of polypeptide ionophores into proteoliposomes reconstituted with rat liver P-glycoprotein. J Biol Chem 1994 0.81
26 Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. J Biol Chem 1996 0.81
27 Characterization of a human alternatively spliced truncated reduced folate carrier increasing folate accumulation in parental leukemia cells. Eur J Biochem 2000 0.81
28 Targeting multidrug resistant tumor cells with a recombinant single-chain FV fragment directed to P-glycoprotein. Int J Cancer 2001 0.80
29 Re: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999 0.79
30 A phenotype conferring selective resistance to lipophilic antifolates in Chinese hamster ovary cells. Cancer Res 1991 0.79
31 New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. Ann Oncol 2010 0.78
32 Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells. Adv Enzyme Regul 1997 0.77
33 Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients. Scand J Rheumatol 2013 0.76
34 Polyamines in the cell cycle of the malarial parasite Plasmodium falciparum. Adv Exp Med Biol 1988 0.75
35 Reduced folate carrier (RFC-1) gene expression in normal and psoriatic skin. Arch Dermatol Res 1998 0.75
36 The reduced folate carrier (RFC-1) gene is expressed in the murine epidermis. Arch Dermatol Res 1998 0.75